Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 43.17 USD -7.16% Market Closed
Market Cap: 2.5B USD
Have any thoughts about
Protagonist Therapeutics Inc?
Write Note

Intrinsic Value

PTGX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one PTGX stock under the Base Case scenario is 18.71 USD. Compared to the current market price of 43.17 USD, Protagonist Therapeutics Inc is Overvalued by 57%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PTGX Intrinsic Value
18.71 USD
Overvaluation 57%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Protagonist Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for PTGX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about PTGX?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Protagonist Therapeutics Inc

Provide an overview of the primary business activities
of Protagonist Therapeutics Inc.

What unique competitive advantages
does Protagonist Therapeutics Inc hold over its rivals?

What risks and challenges
does Protagonist Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Protagonist Therapeutics Inc recently?

Summarize the latest earnings call
of Protagonist Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Protagonist Therapeutics Inc.

Provide P/S
for Protagonist Therapeutics Inc.

Provide P/E
for Protagonist Therapeutics Inc.

Provide P/OCF
for Protagonist Therapeutics Inc.

Provide P/FCFE
for Protagonist Therapeutics Inc.

Provide P/B
for Protagonist Therapeutics Inc.

Provide EV/S
for Protagonist Therapeutics Inc.

Provide EV/GP
for Protagonist Therapeutics Inc.

Provide EV/EBITDA
for Protagonist Therapeutics Inc.

Provide EV/EBIT
for Protagonist Therapeutics Inc.

Provide EV/OCF
for Protagonist Therapeutics Inc.

Provide EV/FCFF
for Protagonist Therapeutics Inc.

Provide EV/IC
for Protagonist Therapeutics Inc.

Show me price targets
for Protagonist Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Protagonist Therapeutics Inc?

How accurate were the past Revenue estimates
for Protagonist Therapeutics Inc?

What are the Net Income projections
for Protagonist Therapeutics Inc?

How accurate were the past Net Income estimates
for Protagonist Therapeutics Inc?

What are the EPS projections
for Protagonist Therapeutics Inc?

How accurate were the past EPS estimates
for Protagonist Therapeutics Inc?

What are the EBIT projections
for Protagonist Therapeutics Inc?

How accurate were the past EBIT estimates
for Protagonist Therapeutics Inc?

Compare the revenue forecasts
for Protagonist Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Protagonist Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Protagonist Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Protagonist Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Protagonist Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Protagonist Therapeutics Inc with its peers.

Analyze the financial leverage
of Protagonist Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Protagonist Therapeutics Inc.

Provide ROE
for Protagonist Therapeutics Inc.

Provide ROA
for Protagonist Therapeutics Inc.

Provide ROIC
for Protagonist Therapeutics Inc.

Provide ROCE
for Protagonist Therapeutics Inc.

Provide Gross Margin
for Protagonist Therapeutics Inc.

Provide Operating Margin
for Protagonist Therapeutics Inc.

Provide Net Margin
for Protagonist Therapeutics Inc.

Provide FCF Margin
for Protagonist Therapeutics Inc.

Show all solvency ratios
for Protagonist Therapeutics Inc.

Provide D/E Ratio
for Protagonist Therapeutics Inc.

Provide D/A Ratio
for Protagonist Therapeutics Inc.

Provide Interest Coverage Ratio
for Protagonist Therapeutics Inc.

Provide Altman Z-Score Ratio
for Protagonist Therapeutics Inc.

Provide Quick Ratio
for Protagonist Therapeutics Inc.

Provide Current Ratio
for Protagonist Therapeutics Inc.

Provide Cash Ratio
for Protagonist Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Protagonist Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Protagonist Therapeutics Inc?

What is the current Free Cash Flow
of Protagonist Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Protagonist Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Protagonist Therapeutics Inc

Current Assets 476.8m
Cash & Short-Term Investments 468.7m
Receivables 2.7m
Other Current Assets 5.4m
Non-Current Assets 127.1m
Long-Term Investments 114.6m
PP&E 12.3m
Other Non-Current Assets 225k
Current Liabilities 44.6m
Accounts Payable 3m
Accrued Liabilities 20.7m
Other Current Liabilities 20.9m
Non-Current Liabilities 27.4m
Other Non-Current Liabilities 27.4m
Efficiency

Earnings Waterfall
Protagonist Therapeutics Inc

Revenue
323.8m USD
Operating Expenses
-174.7m USD
Operating Income
149.1m USD
Other Expenses
21.7m USD
Net Income
170.8m USD

Free Cash Flow Analysis
Protagonist Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

PTGX Profitability Score
Profitability Due Diligence

Protagonist Therapeutics Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Exceptional ROIC
Exceptional ROE
43/100
Profitability
Score

Protagonist Therapeutics Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

PTGX Solvency Score
Solvency Due Diligence

Protagonist Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Protagonist Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PTGX Price Targets Summary
Protagonist Therapeutics Inc

Wall Street analysts forecast PTGX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PTGX is 53.77 USD with a low forecast of 43.43 USD and a high forecast of 68.25 USD.

Lowest
Price Target
43.43 USD
1% Upside
Average
Price Target
53.77 USD
25% Upside
Highest
Price Target
68.25 USD
58% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PTGX?

Click here to dive deeper.

Dividends

Protagonist Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for PTGX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

PTGX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

PTGX News

Other Videos

Profile

Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.6B USD

Dividend Yield

0%

Description

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark California, California and currently employs 118 full-time employees. The company went IPO on 2016-08-11. The firm uses its peptide technology platform to discover and develop peptide-based drugs to address unmet medical needs. Its clinical programs address two categories of diseases, which includes hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. The Company’s alpha-4-beta-7 (α4β7) antagonist PN-943 and its Interleukin-23 receptor (IL-23R) antagonist compound PN-235 are orally delivered investigational drugs that are designed to block biological pathways. PN-943 is an investigational, orally delivered, gut-restricted α4β7 specific integrin antagonist for inflammatory bowel disease (IBD). Its PN-235 is an orally delivered IL-23R specific antagonist for the treatment of IBD and non-IBD indications.

Contact

CALIFORNIA
Newark California
7707 Gateway Blvd Ste 140
+15104740170.0
www.protagonist-inc.com

IPO

2016-08-11

Employees

118

Officers

CEO, President, Secretary & Director
Dr. Dinesh V. Patel Ph.D.
Executive VP & Chief Financial Officer
Mr. Asif Ali
Chief Development Officer
Dr. Suneel K. Gupta Ph.D.
Founder & VP Technology
Dr. Mark Smythe Ph.D.
Executive VP & Chief Technical Officer
Mr. Mohammad Masjedizadeh Ph.D.
Executive VP & General Counsel
Mr. Matthew M. Gosling
Show More
Head of HR & Senior VP of Human Resources
Ms. Carena Spivey
Executive VP & Chief Drug Discovery and Preclinical Development Officer
Dr. Ashok Bhandari Ph.D.
Executive Vice President of Business Development
Mr. Carter J. King
Executive Vice President of Portfolio & Program Management
Ms. Abha Bommireddi
Show Less

See Also

Discover More
What is the Intrinsic Value of one PTGX stock?

The intrinsic value of one PTGX stock under the Base Case scenario is 18.71 USD.

Is PTGX stock undervalued or overvalued?

Compared to the current market price of 43.17 USD, Protagonist Therapeutics Inc is Overvalued by 57%.

Back to Top